- Home
- APM vs CDT Comparison
APM vs CDT Comparison
Compare APM & CDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- CDT
- Stock Information
- Founded
- APM 2010
- CDT 2019
- Country
- APM United Kingdom
- CDT United States
- Employees
- APM N/A
- CDT N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- CDT Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- CDT Health Care
- Exchange
- APM Nasdaq
- CDT Nasdaq
- Market Cap
- APM 5.6M
- CDT 5.2M
- IPO Year
- APM 2018
- CDT N/A
- Fundamental
- Price
- APM $0.99
- CDT $0.54
- Analyst Decision
- APM
- CDT
- Analyst Count
- APM 0
- CDT 0
- Target Price
- APM N/A
- CDT N/A
- AVG Volume (30 Days)
- APM 138.3K
- CDT 7.4M
- Earning Date
- APM 05-06-2025
- CDT 05-13-2025
- Dividend Yield
- APM N/A
- CDT N/A
- EPS Growth
- APM N/A
- CDT N/A
- EPS
- APM 0.00
- CDT N/A
- Revenue
- APM N/A
- CDT N/A
- Revenue This Year
- APM $157,729.10
- CDT N/A
- Revenue Next Year
- APM N/A
- CDT N/A
- P/E Ratio
- APM $270.99
- CDT N/A
- Revenue Growth
- APM N/A
- CDT N/A
- 52 Week Low
- APM $0.46
- CDT $0.51
- 52 Week High
- APM $7.49
- CDT $350.00
- Technical
- Relative Strength Index (RSI)
- APM 51.54
- CDT 36.40
- Support Level
- APM $0.79
- CDT $0.52
- Resistance Level
- APM $0.97
- CDT $1.01
- Average True Range (ATR)
- APM 0.12
- CDT 0.16
- MACD
- APM 0.02
- CDT 0.02
- Stochastic Oscillator
- APM 33.74
- CDT 3.43
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About CDT Conduit Pharmaceuticals Inc.
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being, prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.